昆山新蕴达生物科技

NewYunda is a clinical-stage biotechnology company based in Kunshan, China, specializing in the development of complex injectable formulations and long-acting drug delivery systems. The company leverages its proprietary microsphere and nanoparticle platforms to create improved versions of existing therapies, focusing on therapeutic areas such as psychiatry, endocrinology, and oncology. NewYunda's pipeline includes long-acting formulations of risperidone, exenatide, and octreotide designed to improve patient compliance and therapeutic outcomes. The company aims to address unmet medical needs through advanced pharmaceutical engineering and high-barrier generic drug development.